We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum antivenom for snakebites. Conventional antivenom is outdated: it's expensive, labor-intensive, works for a single species of snake, can only be administered in a hospital, must be kept cold, and has a host of negative side effects for the patient. Our first product, Vipax, elegantly solves these problems while being cheaper to produce. [Read More]
A safe is a Simple Agreement for Future Equity. An investor makes a cash investment in a company, but gets company stock at a later date, in connection with a specific event. A safe is not a debt instrument, but is intended to be an alternative to convertible notes that is beneficial for both companies and investors.
February 23, 2019
March 31, 2019
Intermediary Fee: 5%
Manufacturing of Product: 45%
Pre-Clinical Testing: 50%
Daniel Dempsey - Founder & CEO
Extensive background in developing antibody drugs and bringing to market. MS Biomedical from UCSD.
Deepankar Roy - Co-founder & COO
Expertise in antibody engineering, Genentech. PhD in Biochem and Molecular Bio from USC.
First $75K investors of this fundraise will invest in a SAFE with a $4M valuation cap and 15% discount.
$25K+ pro rata right threshold